Taro Pharmaceuticals USA Inc.
Hawthorne, New York, 10532, United States
NCT Number: NCT02932878
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
Looking for future studies?
Notify Me2 year–18 year
All sexes
Interventional
Phase 2
Hawthorne, New York, 10532, United States
To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to moderate plaque psoriasis.
To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to patients with mild to moderate plaque psoriasis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
topical treatment
Other names: active
Time frame: 28 Days
Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin
Looking for future studies?
Notify MeSun Pharmaceutical Industries, Inc.
Industry
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06488664
Plaque Psoriasis
Barnaul, Russia
View Trial DetailsNCT07008547
Plaque Psoriasis
Beijing, Beijing Municipality, China
View Trial DetailsNCT06088199
Plaque Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT07357831
Plaque Psoriasis
Wuhu, Anhui, China
View Trial Details